StockData

Alnylam Pharmaceuticals vs Insmed

ALNY and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and INSM compare

Alnylam Pharmaceuticals and Insmed are about the same size, with market caps of $22.1B and $24.6B.

Insmed scores higher on the StockData Score (8 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYINSM
Size and price
Market cap$22.1B$24.6B
Share price$165.00$112.58
Change, 1 year−65.7%−32.6%
Change, 5 years−11.9%237%
Beta (5Y)0.880.79
Employees2,5001,664
StockData Score
Total score78 (better)
Valuation score00
Growth score13 (better)
Performance score12 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S–16.2×
P/B6.1× (better)33.9×
FCF yield–−2.6%
Fair value–$61.67
Margin of safety–−82.5%
Growth
Revenue growth (TTM)–240%
Revenue growth, 5Y average49.8% (better)29.8%
Net income growth (TTM)2137%–
Profitability
Gross margin–84.4%
Operating margin–−37.1%
Net margin–−39.9%
FCF margin–−41.3%
Return on equity127% (better)−72.5%
Financial health
Debt / equity0.000.76 (better)
Interest coverage–−6.9×
Current ratio2.482.86 (better)
Altman Z-score2.756.56 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.8%103%
Held by insiders0.49%0.88%
Insider net buying, 12 months−$43.6M (better)−$167M
Superinvestors holding–1
Short interest, % of float5.8%6.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.